- Stocks
- Pharma & Healthcare
- Royal Sense
Royal Sense share price
NSE: ROYALPharma & HealthcareMedical Distribution
Royal Sense at a glance
With a market capitalisation of ₹59 Cr, it ranks 2975th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.
Its return on equity was 17.7% in FY26. Promoters held 62.24% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹59 CrRank 2975 on NSE
- Price to book
- 1.65×FY26
- ROE
- 17.7%FY26
- ROCE
- 26.1%FY26
- Debt to equity
- 0.32FY26
- Net profit margin
- 6.9%FY26
- Book value / share
- ₹75.69FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Royal Sense financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹18 Cr | ₹62 Cr | — |
| Operating profit | ₹2 Cr | ₹9 Cr | — |
| Net profit | ₹2 Cr | ₹6 Cr | — |
| EPS (₹) | ₹6.00 | ₹13.00 | — |
| Cash from operations | −₹4 Cr | ₹1 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Shareholders' equity | ₹18 Cr | ₹28 Cr | ₹40 Cr |
Royal Sense shareholding pattern
| Holder | 31 Mar 2024 | 30 Sep 2024 | 31 Mar 2025 | 8 May 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 67.96% | 67.96% | 67.03% | 62.24% | 62.24% | 62.24% |
| Non-institutions | 32.04% | 32.04% | 32.97% | 37.76% | 37.76% | 37.76% |
Royal Sense vs peers
The listed Pharma & Healthcare companies nearest to Royal Sense by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SAMRATPHSamrat Pharma | — | — | — | ₹61 Cr | — | — |
| ROYALRoyal Sense | — | — | — | ₹59 Cr | — | — |
| BACPHARBacil Pharma | — | — | — | ₹58 Cr | — | — |
| VEERHEALTHVeerhealth Care | — | — | — | ₹58 Cr | — | — |
| CONSTRONICConstronics Inf | — | — | — | ₹57 Cr | — | — |
| KABRADGKabra Drugs | — | — | — | ₹56 Cr | — | — |
| BANDARAMBandaram Pharma | — | — | — | ₹53 Cr | — | — |
Ask anything about Royal Sense
Pivot answers on the live chart with evidence you can check, and tests strategies against ROYAL's own history. Try: “Why has ROYAL moved over the last three months?” · “Backtest a 50-day moving-average crossover on ROYAL over five years” · “Compare ROYAL with SAMRATPH on margins and valuation”
Frequently asked questions about Royal Sense
What is the market cap of Royal Sense?
Royal Sense's market capitalisation is ₹59 Cr (₹59 Cr) at the 22 Oct 2026 close, ranking 2975th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Royal Sense?
Return on equity was 17.7% in FY26 and return on capital employed was 26.1% in FY26 (consolidated figures).
Is Royal Sense a debt-free company?
No. Royal Sense's debt-to-equity ratio was 0.32 in FY26, with total debt of ₹1 Cr.
What is the shareholding pattern of Royal Sense?
As of 31 Mar 2026: promoters 62.24%, non-institutions 37.76%.
Who are Royal Sense's competitors?
The listed Pharma & Healthcare companies closest to Royal Sense by market cap are Samrat Pharma, Bacil Pharma, Veerhealth Care, Constronics Inf, Kabra Drugs and Bandaram Pharma.
Is Royal Sense a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Royal Sense's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ROYAL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with R · all NSE stocks · this page as text